PET and SPECT in Brain Tumors and Epilepsy

被引：14

作者：

Horky, Laura L. ^{[1
]}

Treves, S. Ted ^{[2
]}

机构：

[1] Harvard Univ, Sch Med, Div Nucl Med & Mol Imaging, Dept Radiol,Brigham & Womens Hosp, Boston, MA 02115 USA

[2] Childrens Hosp Boston, Dept Radiol, Div Nucl Med & Mol Imaging, Boston, MA 02115 USA

来源：

NEUROSURGERY CLINICS OF NORTH AMERICA | 2011年 / 22卷 / 02期

关键词：

Molecular imaging; Positron emission tomography; Brain tumor; Epilepsy; POSITRON-EMISSION-TOMOGRAPHY; TEMPORAL-LOBE EPILEPSY; BENZODIAZEPINE-RECEPTOR-BINDING; F-18; FLUORODEOXYGLUCOSE; FDG-PET; TUBEROUS SCLEROSIS; ICTAL SPECT; LOW-GRADE; DIFFERENTIAL-DIAGNOSIS; IMAGING PROLIFERATION;

D O I：

10.1016/j.nec.2010.12.003

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Molecular imaging with positron emission tomography (PET) plays an important role in the diagnosis and management of patients with brain tumors and epilepsy. The clinical uses of FDG are discussed, as well as the research applications of novel PET tracers. Where applicable, single-photon emission computed tomography (SPECT) is also discussed.

引用

页码：169 / +

页数：17

共 109 条

[1]

American Cancer Society, 2009, CANC FACTS FIG REP 2

[2] DIAGNOSIS OF CEREBRAL LESIONS BY THALLIUM 201 [J].